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L E T T E R  T O  T H E  E D I T O R
Cost analysis of dexmedetomidine versus propofol during the 
implantation of a neurostimulator
To the Editor,
Recently, we published a study entitled: “Dexmedetomidine vs 
propofol as sedation for implantation of neurostimulators: A sin-
gle-center single-blinded randomized controlled trial” in the Acta 
Anaesthesiologica Scandinavica.1
This randomized controlled trial compared dexmedetomidine 
with propofol during the implantation of a neurostimulator.2-4 
During the lead implantation of most spinal cord neurostimulators, 
the patient has to be comfortable and without pain. However, the 
patient is expected to provide feedback during electrical mapping. 
Titrating sedatives and analgesics for this double goal can be chal-
lenging. Dexmedetomidine sedation resulted in higher patient sat-
isfaction and allowed for better arousable sedation than sedation 
with propofol. Differences in hemodynamic parameters were found 
between the groups, but not regarded as clinically relevant.
This recent analysis is an addition to the above mentioned study.
There were three motives to study the financial impact of dexme-
detomidine vs propofol during the implantation of a neurostimulator.
First, notwithstanding the results of our abovementioned study, 
several anesthesiologists in our center did not consider the use of 
dexmedetomidine during the implantation of a neurostimulator. As 
dexmedetomidine has only recently been approved—in 2018—for 
sedation analgesia by the European Medicines Agency (EMA), they 
assumed the use of dexmedetomidine to be more expensive than 
that of propofol.
Second, a European economic evaluation of the use of dexmedeto-
midine in intensive care units showed unexpectedly that dexmedeto-
midine sedation was more cost-effective than the standard sedatives 
propofol and midazolam.4 This, despite the long required duration of ad-
ministration compared to that in the implantation of a neurostimulator.5
Third, although the costs of a procedure are important in them-
selves, the quality of the health care from the perspective of the pa-
tient, is increasingly seen as important. Considering this view and the 
results of our previous study, that is, the higher patient satisfaction 
and the allowance for better arousable sedation using dexmedetomi-
dine compared to propofol, would justify a potential higher cost to a 
certain extent and was an additional reason to perform this analysis.
The cost analysis was conducted from the hospital perspective in 
2018. The included costs associated with the procedure were those of 
the sedative agents, the other medications and the neurostimulation 
procedure. Costs were measured during the period between the start 
of the procedure and the patient's discharge from the recovery room.
The costs of the use of dexmedetomidine were significantly 
higher than the costs of the use of propofol (see Table 1). The results 
of sensitivity analysis were found to be consistent with this finding, 
with the exception of the original variant of propofol.
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TA B L E  1   Results of the base case analysis and sensitivity analysis regarding costs of medication
 
Dexmedetomidine 
group (n = 35)
Propofol group 
(n = 34)    
Costs per 
ampoule/flacon
Base case: €23.44a 
Sens 1: €22.79b 
Base case: €1.05a 
Sens 2: €9.56b 
Sens 3: €36.68b 
   
 Mean (min - max) SD Mean (min - max) SD
Cost 
difference 95% CI P-value
Sedative cost Base case: €8.77a 
(€2.03 - €17.26)
Sens 1: €8.53b 
(€1.97 – €16.78)
4.2
4.1
Base case: €0.51a 
(€0.04 – €2.07)
Sens 2: €4.66b 
(€0.38 – €18.88)
Sens 3: €17.86b 
(€1.45 – €72.45)
0.4
3.9
15.1
€8.26
€3.87
€-9.33
[6.8, 9.7]
[1.9, 5.8]
[−14.6, −4.1]
<.01
<.01
<.01
aBase case: price in Erasmus University Medical Center. 
bSensitivity range: price extracted from “The Netherlands National Health Care Institute Medication Costs” (searchable database (in Dutch) of 
medicine prices (September 20186), Sens 1: price of the original variant of dexmedetomidine, Sens 2: price of the generic variant of propofol, Sens 3: 
price of the original variant of propofol, sedative cost = mean costs per the amount of sedative agent used. 
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Considering that the mean unit cost of a neurostimulation pro-
cedure varied from €5.018,50 for a trial implant to €22.885,33 for a 
definitive implantation, the sedation costs represented only <0.5% 
of the total costs associated with a neurostimulation procedure, 
both for a trial implant and a definitive implant.
The cost difference between the use of propofol and dexmede-
tomidine during the implantation of a neurostimulator is statistically 
significant but factually small. Based on these considerations and on 
the benefits to the patient when using dexmedetomidine instead of 
propofol we believe that the choice for dexmedetomidine as a seda-
tive is preferable and justified.
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